Supernus Pharmaceuticals reported $17.93M in Cost of Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Abbott ABT:US $ 4987M 267M
Aerie Pharmaceuticals AERI:US $ 6.78M 0.71M
Ani Pharmaceuticals ANIP:US $ 34.27M 373K
Aurora Cannabis Inc ACB:CN 103.36M 6.41M
Bristol Myers Squibb BMY:US $ 2471M 115M
Canopy Growth Corp WEED:CN C$ 271.01M 140.13M
Corcept Therapeutics CORT:US $ 1.25M 0.1M
Eisai 4523:JP Y 50738M 6516M
Eli Lilly And LLY:US $ 2072.1M 21.9M
Endo International Ordinary Shares ENDP:US $ 179.76M 42.71M
Horizon Pharma HZNP:US $ 215.06M 26.45M
JAZZ PHA JAZZ:US $ 115.28M 20.87M
Lannett LCI:US $ 75.28M 5.52M
Pacira Pharmaceuticals PCRX:US $ 36.07M 2.93M
Perrigo Ordinary Shares PRGO:US $ 736.7M 5.8M
Revance Therapeutics RVNC:US $ 7.89M 12K
Supernus Pharmaceuticals SUPN:US $ 17.93M 0.94M
Teva Pharmaceutical Industries TEVA:US $ 1859M 116M
United Therapeutics UTHR:US $ 25.9M 8.7M
Xeris Pharmaceuticals Inc XERS:US $ 6.27M 1.38M